Rescue of functional CFTR channels in cystic fibrosis: a dramatic multivalent effect using iminosugar cluster-based correctors
- PMID: 24038832
- DOI: 10.1002/cbic.201300312
Rescue of functional CFTR channels in cystic fibrosis: a dramatic multivalent effect using iminosugar cluster-based correctors
Abstract
Cystic fibrosis is caused by a mutation in the gene for the cystic fibrosis transmembrane conductance regulator (CFTR) protein. N-butyl 1-deoxynojirimycin (N-Bu DNJ), a clinical candidate for the treatment of cystic fibrosis, is able to act as a CFTR corrector by overcoming the processing defect of the mutant protein. To explore the potential of multivalency on CFTR correction activity, a library of twelve DNJ click clusters with valencies ranging from 3 to 14 were synthesized. Significantly, the trivalent analogues were found to be up to 225-fold more potent than N-Bu DNJ and up to 1000-fold more potent than the corresponding monovalent models. These results provide the first description of a multivalent effect for correcting protein folding defects in cells and should have application for the treatment of a number of protein folding disorders. Preliminary mechanistic studies indicated that CFTR correction activity enhancement was not due to a multivalent effect in ER-glucosidase inhibition or to a different mode of action of the multivalent iminosugars.
Keywords: CFTR correctors; cystic fibrosis; iminosugars; multivalency; protein folding diseases.
Copyright © 2013 WILEY-VCH Verlag GmbH & Co. KGaA, Weinheim.
Similar articles
-
An overview on chemical structures as ΔF508-CFTR correctors.Eur J Med Chem. 2019 Oct 15;180:430-448. doi: 10.1016/j.ejmech.2019.07.037. Epub 2019 Jul 15. Eur J Med Chem. 2019. PMID: 31326599 Review.
-
Correctors of the basic trafficking defect of the mutant F508del-CFTR that causes cystic fibrosis.Curr Opin Chem Biol. 2013 Jun;17(3):353-60. doi: 10.1016/j.cbpa.2013.04.020. Epub 2013 May 24. Curr Opin Chem Biol. 2013. PMID: 23711435 Review.
-
A chemical corrector modifies the channel function of F508del-CFTR.Mol Pharmacol. 2010 Sep;78(3):411-8. doi: 10.1124/mol.110.065862. Epub 2010 May 25. Mol Pharmacol. 2010. PMID: 20501743
-
Dynasore inhibits removal of wild-type and DeltaF508 cystic fibrosis transmembrane conductance regulator (CFTR) from the plasma membrane.Biochem J. 2009 Jul 15;421(3):377-85. doi: 10.1042/BJ20090389. Biochem J. 2009. PMID: 19442237
-
Specific rescue of cystic fibrosis transmembrane conductance regulator processing mutants using pharmacological chaperones.Mol Pharmacol. 2006 Jul;70(1):297-302. doi: 10.1124/mol.106.023994. Epub 2006 Apr 19. Mol Pharmacol. 2006. PMID: 16624886
Cited by
-
Tuning the activity of iminosugars: novel N-alkylated deoxynojirimycin derivatives as strong BuChE inhibitors.J Enzyme Inhib Med Chem. 2021 Dec;36(1):138-146. doi: 10.1080/14756366.2020.1847101. J Enzyme Inhib Med Chem. 2021. PMID: 33228403 Free PMC article.
-
Synthesis and Glycosidase Inhibition Properties of Calix[8]arene-Based Iminosugar Click Clusters.Pharmaceuticals (Basel). 2020 Nov 5;13(11):366. doi: 10.3390/ph13110366. Pharmaceuticals (Basel). 2020. PMID: 33167387 Free PMC article.
-
Synthesis and Therapeutic Applications of Iminosugars in Cystic Fibrosis.Int J Mol Sci. 2020 May 9;21(9):3353. doi: 10.3390/ijms21093353. Int J Mol Sci. 2020. PMID: 32397443 Free PMC article. Review.
-
Innovative Therapies for Cystic Fibrosis: The Road from Treatment to Cure.Mol Diagn Ther. 2019 Apr;23(2):263-279. doi: 10.1007/s40291-018-0372-6. Mol Diagn Ther. 2019. PMID: 30478715 Review.
-
Prevalence of abnormal glucose metabolism in pediatric acute, acute recurrent and chronic pancreatitis.PLoS One. 2018 Oct 31;13(10):e0204979. doi: 10.1371/journal.pone.0204979. eCollection 2018. PLoS One. 2018. PMID: 30379828 Free PMC article.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Other Literature Sources
Medical